Delving into the Latest Updates on CAStem Cell (Beijing Zehui Chenxing) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms

人胚干细胞（hESC）（北京泽辉辰星）

Target-

Mechanism

Cell replacements

Therapeutic Areas

Immune System DiseasesRespiratory DiseasesOther Diseases+ [1]

Active Indication

Acute Graft Versus Host DiseaseLung Diseases, InterstitialRespiratory Distress Syndrome, Acute+ [2]

Inactive Indication-

Originator Organization

Beijing Zehui Chenxing Biotechnology Co., Ltd.

Active Organization

Beijing Zehui Chenxing Biotechnology Co., Ltd.

Institute of Zoology Chinese Academy of Science

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价CAStem细胞注射液治疗急性呼吸窘迫综合征（ARDS）的初步有效性。次要目的：评价CAStem细胞注射液治疗ARDS的安全性和耐受性。探索性目的：探索CAStem细胞注射液治疗前后外周血和肺泡灌洗液生物标志物变化以及与疗效之间的潜在关系。

[Translation]

Primary objective: To evaluate the preliminary efficacy of CAStem cell injection in the treatment of acute respiratory distress syndrome (ARDS). Secondary objective: To evaluate the safety and tolerability of CAStem cell injection in the treatment of ARDS. Exploratory objective: To explore the changes in biomarkers in peripheral blood and bronchoalveolar lavage fluid before and after CAStem cell injection treatment and their potential relationship with efficacy.

Start Date10 Dec 2022

Sponsor / Collaborator

Beijing Zehui Chenxing Biotechnology Co., Ltd.

100 Clinical Results associated with CAStem Cell (Beijing Zehui Chenxing)

Login to view more data

100 Translational Medicine associated with CAStem Cell (Beijing Zehui Chenxing)

Login to view more data

100 Patents (Medical) associated with CAStem Cell (Beijing Zehui Chenxing)

Login to view more data

100 Deals associated with CAStem Cell (Beijing Zehui Chenxing)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Graft Versus Host Disease	Phase 2	CN	Beijing Zehui Chenxing Biotechnology Co., Ltd.	18 Jul 2023
Lung Diseases, Interstitial	Phase 2	CN	Beijing Zehui Chenxing Biotechnology Co., Ltd.	04 Jul 2023
Respiratory Distress Syndrome, Acute	Phase 2	CN	Beijing Zehui Chenxing Biotechnology Co., Ltd.	10 Dec 2022
Meniscus disorder	Phase 2	CN	Beijing Zehui Chenxing Biotechnology Co., Ltd.	04 Mar 2022
Meniscus disorder	Phase 2	CN	Institute of Zoology Chinese Academy of Science	04 Mar 2022
Respiratory Distress Syndrome, Adult	IND Approval	CN	Beijing Zehui Chenxing Biotechnology Co., Ltd.	14 Feb 2022